MARINUS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Marinus Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. for allegedly making materially false and misleading statements regarding its business operations and clinical trials [1][6]. Summary by Relevant Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased or acquired Marinus securities between March 17, 2021, and May 7, 2024, inclusive [1]. - Investors have until August 5, 2024, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against Marinus - The lawsuit claims that Marinus defendants understated the risk of failing to meet early-stopping criteria in the RAISE trial [6]. - It is alleged that the defendants did not disclose that failing to meet these criteria could lead to the cessation of the separate Phase 3 RAISE II trial [6]. - As a result, the statements made by the defendants regarding the company's business, operations, and prospects were materially false and misleading [6].